DPP4 and type 2 diabetes mellitus: In this study, we used Taiwan’s National Health Insurance (NHI) database to determine associations between SGLT2i-use and deaths when compared with Dipeptidyl peptidase 4 inhibitor (DPP4i)-use for T2DM.